BiondVax
 | This article contains content that is written like an advertisement. (August 2023) |
 |
 | |
| Company type | Public |
|---|---|
| Nasdaq: BVXV | |
| Industry | Pharmaceuticals |
| Founded | 2003 |
| Headquarters | , Israel |
Number of employees | 30 (2022) |
| Website | www |
BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases.
In collaboration with the Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax develops nanosized antibody (NanoAb) therapies for diseases such as COVID-19, asthma and psoriasis.
History
Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and owns and operates a biologics manufacturing facility for housing its laboratories, production facilities and offices.
In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences – and the UMG to enter into a strategic collaboration for the development and commercialization of COVID-19 NanoAbs.
See also
References
- Articles with a promotional tone from August 2023
- All articles with a promotional tone
- Articles lacking sources from August 2023
- All articles lacking sources
- Articles with short description
- Short description is different from Wikidata
- Companies listed on the Nasdaq
- Biopharmaceutical companies
- Pharmaceutical companies of Israel